Surgery · Medical Literature
Postoperative Analgesia and Recovery with Liposomal Bupivacaine TAP/RSB Block in Elderly Patients Undergoing Laparoscopic Inguinal Hernia Repair: A Randomized Controlled Trial.
Abstract
Older adults undergoing laparoscopic transabdominal preperitoneal (TAPP) hernia repair often experience inadequate analgesia and delayed mobilization. We tested the hypothesis that dual-plane abdominal wall blocks (transversus abdominis plane + rectus sheath block, TAP+RSB) using liposomal bupivacaine (LB) improve opioid-sparing and recovery versus standard bupivacaine (BP) or no block. In this single-center, randomized, three-arm trial, 147 patients aged ≥70 years were assigned 1:1:1 to LB‑TAP+RSB (LB group, n=49), BP‑TAP+RSB (BP group, n=49), or no block (control, n=49). Anaesthesia was standardised to maintain BIS 40-60. The primary outcome was 48‑hour opioid consumption (intravenous morphine equivalents). Secondary outcomes included time to first rescue analgesia, pain scores at rest/on movement, time to ambulation, time to extubation, length of stay, and adverse events. Total opioid use was significantly lower in both block groups versus control (BP: -5.53 mg, 95% CI -8.08 to -2.99; LB: -7.24 mg, 95% CI -9.80 to -4.69). Fewer LB patients needed early rescue analgesia than controls (2.0% vs 18.4%, OR 0.10, 95% CI 0.01-0.84). At 8 h, rest pain was lower with LB (P=0.007). Ambulation time was shortest with LB (14.1±2.5 h) compared with BP (16.7±6.5 h) and control (20.0±6.2 h) (both P≤0.006). Extubation occurred earlier in block groups (LB/BP median 2 min vs control 6 min, P<0.001). Hospital stay was shorter with blocks (median 3 vs 4 days, P<0.001). Adverse events did not differ between groups. Dual-plane TAP+RSB, particularly with LB, reduces opioid need and speeds recovery in older TAPP patients, supporting its use in ERAS pathways.
Clinical relevance
In patients aged ≥70 years undergoing laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair, does a dual-plane abdominal wall block (TAP + rectus sheath block) using liposomal bupivacaine reduce 48-hour opioid consumption and improve recovery outcomes compared to standard bupivacaine block or no block? __SNAPSHOT__ {"studyDesign":"Single-center, prospective, three-arm randomized controlled trial","setting":"Single center; country not reported in abstract; inpatient surgical setting","sampleSize":"n=147 (LB-TAP+RSB: n=49; BP-TAP+RSB: n=49; no-block control: n=49)","population":"Adults aged ≥70 years undergoing elective laparoscopic TAPP inguinal hernia repair under general anesthesia with standardized BIS-guided (target 40–60) anesthetic management","intervention":"Dual-plane abdominal wall block (transversus abdominis plane block + rectus sheath block [TAP+RSB]) using liposomal bupivacaine (LB), a multivesicular sustained-release formulation designed to provide analgesia for up to 72 hours","comparator":"Two active comparators: (1) TAP+RSB using standard (plain) bupivacaine (BP); (2) no block (control)","primaryOutcome":"Total opioid consumption over 48 hours postoperatively, expressed as intravenous morphine equivalents (mg)","followUp":"48 hours (primary outcome); additional secondary outcomes assessed perioperatively through hospital discharge","fundingSource":"Not reported"}
Key findings
Both block groups demonstrated statistically significant reductions in 48-hour opioid consumption versus the no-block control. The plain bupivacaine TAP+RSB block reduced opioid use by a mean of 5.53 mg IV morphine equivalents (95% CI: −8.08 to −2.99 mg) compared to control. The liposomal bupivacaine TAP+RSB block reduced opioid use by a mean of 7.24 mg IV morphine equivalents (95% CI: −9.80 to −4.69 mg) compared to control. P-values for these pairwise comparisons were not reported in the abstract. The incremental benefit of LB over BP (difference of 1.71 mg [calculated]) was not accompanied by a reported p-value or confidence interval for that specific head-to-head comparison in the abstract. Regarding rescue analgesia, early rescue analgesia was required by only 2.0% of LB patients versus 18.4% of controls (OR 0.10, 95% CI 0.01–0.84), suggesting a clinically meaningful reduction in early analgesic failure. The corresponding comparison between LB and BP, or between BP and control, for this endpoint was not reported in the abstract. Secondary recovery outcomes favored block groups: time to first ambulation was shortest in the LB group (14.1 ± 2.5 h) compared to BP (16.7 ± 6.5 h) and control (20.0 ± 6.2 h), with both comparisons reaching statistical significance at P ≤ 0.006. Extubation time was shorter in both block groups (LB and BP median 2 min) versus control (median 6 min; P < 0.001). Hospital length of stay was shorter with either block versus control (median 3 days vs. 4 days; P < 0.001). Adverse event rates did not differ statistically between groups. No specific adverse events were quantified in the abstract. NNT for early rescue analgesia avoidance (LB vs. control): approximately 6.1 (calculated from 18.4% vs. 2.0% event rates).
Practice implications
This trial provides RCT-level evidence that dual-plane TAP+RSB using either plain bupivacaine or liposomal bupivacaine reduces 48-hour opioid consumption and improves multiple recovery metrics in elderly patients (≥70 years) undergoing laparoscopic TAPP hernia repair, compared to no regional analgesia. The ~7 mg morphine-equivalent reduction with LB and ~5.5 mg reduction with BP, while modest in absolute terms, may carry heightened clinical relevance in older adults who are particularly sensitive to opioid-related adverse effects (e.g., delirium, respiratory depression, falls, ileus). The earlier ambulation (≈6 hours sooner with LB vs. control) and one-day reduction in hospital stay in block groups are clinically meaningful in a geriatric ERAS context. Whether the incremental opioid reduction of LB over BP (~1.7 mg, calculated) is clinically important remains uncertain, as no formal head-to-head comparison statistics between LB and BP are reported in the abstract. The trial does not establish whether the block benefit is driven primarily by early opioid reduction, reduction in peak opioid exposure, or modulation of the surgical stress response. The single-center design, exclusively elderly male hernia patients, and unspecified blinding methodology limit generalizability to broader hernia populations, bilateral repairs, younger adults, or other laparoscopic abdominal procedures. The absence of longer-term outcomes (e.g., 7- or 30-day pain, chronic pain rates) is a notable gap. IMPORTANT NOTE: Only the abstract was available for this summary; full methodology, randomization details, allocation concealment, blinding procedures, and complete statistical analyses require review of the full manuscript for definitive interpretation. __LIMITATIONS__ Single-center design limits generalizability across different practice settings and surgical volume contexts.,Abstract does not report whether participants, outcome assessors, or care providers were blinded to group allocation — a critical source of performance and detection bias for subjective outcomes such as pain scores.,Sample size of 49 per arm may be underpowered to detect the incremental difference between LB and BP groups; no formal head-to-head LB vs. BP statistical comparison is reported in the abstract for the primary outcome.,Exclusively elderly patient population (≥70 years) undergoing a single procedure (TAPP hernia repair) at one center; findings may not generalize to younger adults, other hernia repair techniques, bilateral repairs, or more complex abdominal surgeries.,Primary endpoint (48-hour IV morphine equivalents) is a short-duration surrogate for functional recovery; no data on chronic postoperative pain, 30-day outcomes, patient-reported functional status, or quality of life are reported.,No universally accepted Minimal Clinically Important Difference (MCID) for 48-hour postoperative morphine consumption exists, making the clinical significance of observed differences subject to interpretation.,Funding source is not reported; potential conflict of interest related to liposomal bupivacaine cannot be excluded.,Adverse events are described only as not differing between groups without reporting specific event types, rates, or severity — particularly relevant given the geriatric population at elevated risk for local anesthetic systemic toxicity.,Standardization of the no-block control group's analgesic rescue protocol and post-discharge pain management is not described in the abstract.,Abstract is truncated, limiting complete extraction of all statistical results and methodological details. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ In patients aged ≥70 years undergoing laparoscopic TAPP hernia repair, dual-plane TAP+RSB with either plain or liposomal bupivacaine significantly reduced 48-hour opioid consumption and shortened time to ambulation and hospital discharge compared to no block, with liposomal bupivacaine providing the greatest reduction in early rescue analgesia needs. The incremental clinical benefit of liposomal bupivacaine over plain bupivacaine is statistically and clinically uncertain based on currently available abstract data. These findings support the integration of TAP+RSB into geriatric ERAS protocols for laparoscopic hernia repair, though confirmation from multi-center trials with robust blinding and longer follow-up is warranted before preferentially recommending the more costly liposomal formulation.